OBJECTIVES: There have been several strict cost containment measures, as reference pricing system and global budget, being aplied in Turkish health care system especially for drugs. As a result of these measures; most of the drugs being marketed in Turkey have the lowest price in Europe. In this regard, several drugs including the drugs being used in critical diseases such as cancer, orphan diseases etc, have been withdrawn from the market or even they wouldn’t be able to enter the market. Therefore, Turkish government brings these drugs from abroad by paying much more money compared to the current or the future prices (the price if the drug would have licenced or being reimbursed) of those drugs in Turkey. The aim of this study is to analyze the list of these drugs according to their ATC groups. METHODS: The list of Social Security Institution (SSI) on drugs bringing from abroad (Annex 4 C) have been analyzed in assistance with RxMediaPharma® Program.  RESULTS: In total, there are 662 drugs being listed in the latest Annex 4-C list. Among this list; the most frequently listed ATC group is L (antineoplastic and immunomodulating agents) by 22%, second is A (alimentary tract and metabolism) by 13.3%, third is C (cardiovascular system) by 12.5%, fourth and fifth are; N (nervous system) by 12% and J (antiinfectives for systemic use) by 6,35% relatively.    CONCLUSIONS: Strict cost containment measures being applied in Turkey causes shortages of several drugs especially the ones being used in diseases with high mortality rates like cancer. In this situation, despite government has brought these medicines from abroad, as this procedure takes some time, patients may have trouble in reaching these drugs on time and SSI pays much more for these drugs compared to their probable prices in Turkey.